Skip to main content
SpringerLink
Log in

Efficacy of Botulinum Therapy in Correcting the Level of Pain Syndrome and Quality of Life in Patients with Cervical Dystonia

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objectives. To assess the severity of pain syndrome, emotional status, and quantitative levels of humoral serotonin in patients with cervical dystonia (CD) before and after botulinum therapy. Materials and methods. A simple open comparative study of the clinical characteristics of hyperkinesia, pain, and emotional status, quality of life, and serum and platelet serotonin levels was conducted in 48 patients with cervical dystonia at age 37–53 years before and one month after botulinum therapy with botulinum toxin A (Dysport) at doses of 500–1000 U. The control group consisted of 15 healthy subjects. Results. All patients presented with complaints of involuntary movements and neck pain. The overall indicator on the dystonic movements scale among the patients was 16.7 ± 7.7 points and the score on the TWSTRS scale was 46.48 ± 6.2 points; the mean visual analog pain score was 6.4 ± 1.08 points. The levels of depression and anxiety on the Hamilton scale were significantly greater in the patients group than in the controls. The levels of reactive and trait anxiety on the Spielberger–Hanin test in patients with CD were significantly (p < 0.005) greater than those in the healthy group. Correlation analysis identified a direct relationship between pain intensity on the TWSTRS scale and the level of anxiety on the Hamilton scale and the total points score for dystonic movements. Serum and platelet serotonin levels were significantly lower than in controls. After botulinum therapy, patients showed significant reductions in pain, anxiety, and depression, while platelet serotonin increased. Conclusions. Botulinum therapy with Dysport decreased the levels of pain and depression in patients with CD, improved quality of life, and stimulated the serotoninergic system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. V. L. Golubev, “Clinical polymorphism and the treatment of muscle dystonia,” Zh. Nevrol. Psikhiat., 91, No. 3, 30–34 (1991).

    CAS  Google Scholar 

  2. S. L. Timerbaeva, Focal and Segmental Forms of Primary Dystonia: Clinical, Pathophysiological, and Molecular-Genetic Aspects: Dissertation for Doctorate in Medical Sciences, Moscow (2012), http://medical-diss.com/medicina/fokalnye-i-segmentarnye-formy-pervichnoy-distonii#ixzz4gP6kHFOd, acc. May 7, 2017.

  3. V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), Extrapyramidal Disorders: Guidelines for Diagnosis and Treatment, MEDpress-inform, Moscow (2002), http://parkinsonizm.ru/?page=91, acc. May 7, 2017.

  4. V. L. Golubev, A. Yu. Makarov, O. R. Orlova, et al., “Clinical and electromyography characteristics of spastic torticollis,” Zh. Nevrol. Psikhiat., 95, No. 4, 40–42 (1995).

    CAS  Google Scholar 

  5. A. Albanese, F. Asmus, K. P. Bhatia, et al., “EFNS guidelines on diagnosis and treatment of primary dystonias,” Eur. J. Neurol., 18, No. 1, 5–18 (2011), https://doi.org/10.1111/j.1468-1331.2010.03042.

    Article  PubMed  CAS  Google Scholar 

  6. J. K. S. Tsui, “Cervical dystonia,” Handbook of Dystonia, J. K. S. Tsui and D. B. Calne (eds.), Marcel Dekker, New York (1995).

  7. O. R. Orlova and H. N. Yakhno, The Use of Botox (Botulinum toxin type A) in Clinical Practice: a Guide for Physicians, The Catalog, Moscow (2000).

    Google Scholar 

  8. D. Tarsy and D. K. Simon, “Dystonia,” N. Engl. J. Med., 355, No. 8, 818–829 (2006), https://doi.org/https://doi.org/10.1056/NEJMc062570.

  9. Y. Ben-Shlomo, L. Camfield, and T. Warner, “What are the determinants of quality of life in people with cervical dystonia?” J Neurol. Neurosurg. Psychiatry, 72, No. 5, 608–614 (2002), https://doi.org/https://doi.org/10.1136/jnnp.72.5.608.

  10. I. A. Ivanova-Smolenskaya, E. D. Markova, and S. N. Illarioshkin, “Monogenic inheritance of nervous system disease,” in: Inherited Diseases of the Nervous System, Yu. E. Vel’tishchev and P. A. Temin (eds.). Meditsina, Moscow (1998).

    Google Scholar 

  11. T. Etgen, M. Mühlau, C. Gaser, and D. Sander, “Bilateral grey-matter increase in the putamen in primary blepharospasm,” J Neurol. Neurosurg. Psychiatry, 77, No. 9, 1017–1020 (2006), https://doi.org/https://doi.org/10.1136/jnnp.2005.087148.

  12. D. Martino, A. Di Giorgio, and E. D’Ambrosio, et al., “Cortical gray matter changes in primary blepharospasm: A voxel-based morphometry study,” Mov. Disord., 26, No. 10, 1907–1912 (2011), https://doi.org/10.1002/mds.23724.

    Article  PubMed  Google Scholar 

  13. O. N. Shcherskaya, Spastic Torticollis (clinical pathogenetic and social aspects): Dissertation for Master’s Degree in Medical Sciences, Moscow (1996), http://medical-diss.com/medicina/spasticheskayakrivosheya, acc. May 7, 2017.

  14. O. R. Orlova, S. L. Timerbaeva, S. E. Khat’kova, et al., “Focal dystonias and their treatment with Dysport (botulinum toxin type A),” Zh. Nevrol. Psikhiat., 112, No. 5, 81–89 (2012).

    CAS  Google Scholar 

  15. M. Jahanshahi, “Factors that ameliorate or aggravate spasmodic torticollis,” J Neurol. Neurosurg. Psychiatry, 68, No. 2, 227–229 (2000), https://doi.org/10.1136/jnnp.68.2.227.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Yu. V. Karakulova, “The pathogenetic mechanisms of tension headache,” Zh. Nevrol. Psikhiat., 106, No. 7, 52–56 (2006).

    Google Scholar 

  17. J. Jancovic, S. Leder, and D. Warner, “Cervical dystonia: Clinical findings and associated movement disorders,” Neurology, 41, 1088–1091 (1991).

    Article  Google Scholar 

  18. Z. A. Zalyalova and D. M. Abdulgalimova, “Pain syndrome before and after the use of Dysport in patients with spastic torticollis,” Zh. Nevrol. Psikhiat., 110, No. 11, 62–65 (2010).

    Google Scholar 

  19. M. Hallett, R. Benecke, A. Blitzer, and C. L. Comella, “Treatment of focal dystonias with botulinum neurotoxin,” Toxicon, 54, No. 5, 628–633 (2009), https://doi.org/10.1016/j.toxicon.2008.12.008.

    Article  PubMed  CAS  Google Scholar 

  20. A. Berardelli, J. C. Rothwell, and M. Hallett, “The pathophysiology of primary dystonia,” Brain, 121, 1195–1212 (1998), https://www.ncbi.nlm.nih.gov/pubmed/9679773, acc. May 7, 2017.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vagner Perm State Medical University, Russian Ministry of Health, Perm, Russia

    Yu. V. Karakulova & N. V. Loginova

Authors
  1. Yu. V. Karakulova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. V. Loginova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu. V. Karakulova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 117, No. 12, Iss. 1, pp. 33–36, December, 2017.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karakulova, Y.V., Loginova, N.V. Efficacy of Botulinum Therapy in Correcting the Level of Pain Syndrome and Quality of Life in Patients with Cervical Dystonia. Neurosci Behav Physi 49, 271–274 (2019). https://doi.org/10.1007/s11055-019-00725-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-019-00725-z

Keywords

Search

Navigation